Table 1.
Effects of cholecalciferol administration on behavioral impairments of OVX rats following long-term estrogen deficiency in the open field test for 5 min.
| Groups | Crossing | Rearing | Grooming |
|---|---|---|---|
| Control rats + solvent | 65.7 ± 3.8 | 14.5 ± 0.8 | 3.8 ± 0.2 |
| Intact rats + diazepam | 32.39 ± 4.2 * | 4.9 ± 0.6 * | 1.4 ± 0.2 * |
| Intact rats + cholecalciferol 1.0 mg/kg | 61.3 ± 2.4 | 12.9 ± 0.8 | 1.6 ± 0.2 * |
| Intact rats + cholecalciferol 2.5 mg/kg | 52.7 ± 4.2 | 13.5 ± 1.0 | 3.4 ± 0.2 |
| Intact rats + cholecalciferol 5.0 mg/kg | 58.1 ± 3.8 | 12.1 ± 0.8 | 3.5 ± 0.2 |
| OVX rats + solvent | 64.5 ± 4.2 | 15.5 ± 0.8 | 1.8 ± 0.2 * |
| OVX rats + diazepam | 34.5 ± 3.2 *,# | 6.1 ± 0.8 *,# | 1.6 ± 0.2 *,# |
| OVX rats + 17β-E2 | 57.9 ± 3.4 | 12.6 ± 0.2 | 3.5 ± 0.4 # |
| OVX rats + diazepam + 17β-E2 | 55.3 ± 4.5*,# | 11.7 ± 0.8 *,# | 2.5 ± 0.5 # |
| OVX rats + cholecalciferol 1.0 mg/kg | 65.2 ± 2.5 | 12.1 ± 0.6 | 4.0 ± 0.2 # |
| OVX rats + cholecalciferol 2.5 mg/kg | 71.5 ± 4.2 | 14.5 ± 1.8 | 3.6 ± 0.2 # |
| OVX rats + cholecalciferol 5.0 mg/kg | 80.9 ± 9.6 | 11.7 ± 1.4 | 3.9 ± 0.2 # |
| OVX rats + cholecalciferol 1.0 mg/kg + 17β-E2 | 90.3 ± 4.6 *,#,## | 12.1 ± 0.6 | 1.5 ± 0.6 *,## |
| OVX rats + cholecalciferol 2.5 mg/kg + 17β-E2 | 98.3 ± 3.4 *,#,## | 15.7 ± 1.6 | 2.2 ± 0.2 *,## |
| OVX rats + cholecalciferol 5.0 mg/kg + 17β-E2 | 64.7 ± 5.6 | 14.5 ± 0.8 | 4.5 ± 0.8 # |
The obtained results show the mean ± standard error of the mean (SEM). *—p < 0.05 as compared to the control group of sham-operated rats, #—p < 0.05 as compared to the OVX rats treated with solvent, ##—p < 0.05 as compared to the OVX rats treated with 17β-estradiol. Each group comprised a minimum of eight rats. Cholecalciferol was given at 1.0, 2.5 or 5.0 mg/kg/day SC, once daily, for 14 days. The administered dose of 17β-E2 was 0.5 µg/rat SC, once daily, for 14 days.